Latest Herantis Pharma News & Updates

See the latest news and media coverage for Herantis Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Herantis Pharma

Clinical-stage neurodegenerative disease drug developer

herantis.com
Headquarters
Espoo, Finland
Founded year
2008
Company type
Public company
Number of employees
20–50

Last updated

Latest news about Herantis Pharma

In short: Herantis Pharma finalized the Phase 2a study design for its Parkinson's therapy HER-096 after receiving positive feedback from the FDA.

Company announcements

Herantis Pharma

Herantis Pharma finalizes Phase 2a study design

FDA raised no CMC or preclinical concerns; the randomized placebo-controlled study will enroll ~100 early-stage Parkinson's patients in Europe, use the Digital Motor Score, has CRO and >50% funding.

Herantis Pharma

Herantis Pharma CEO and CSO discuss Parkinson's trial and funding

They cover HER-096 design, Phase 1b results, share issue, grant, and upcoming catalysts.

Unlock all announcements with a

Media coverage

Markets Insider

Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer's & Parkinson's Diseases

Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson's disease, announces that its Chief Scientific Officer, Henri Huttunen...

Unlock all articles with a

Never miss news about Herantis Pharma

Track Herantis Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Herantis Pharma competitors & trending companies

Browse news for competitors to Herantis Pharma and other trending companies.